Exploring the Effects of Omalizumab in Allergic Asthma
Top Cited Papers
- 15 April 2013
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 187 (8), 804-811
- https://doi.org/10.1164/rccm.201208-1414oc
Abstract
For many patients with asthma, allergic airway inflammation is primarily a Th2-weighted process; however, heterogeneity in patterns of inflammation suggests phenotypic distinctions exist that influence disease presentation and treatment effects. To assess the potential of fractional exhaled nitric oxide (FE(NO)), peripheral blood eosinophil count, and serum periostin as biomarkers of Th2 inflammation and predictors of treatment effects of omalizumab. The EXTRA omalizumab study enrolled patients (aged 12-75 yr) with uncontrolled severe persistent allergic asthma. Analyses were performed evaluating treatment effects in relation to FE(NO), blood eosinophils, and serum periostin at baseline. Patients were divided into low- and high-biomarker subgroups. Treatment effects were evaluated as number of protocol-defined asthma exacerbations during the 48-week treatment period (primary endpoint). A total of 850 patients were enrolled. Data were available from 394 (46.4%), 797 (93.8%), and 534 (62.8%) patients for FE(NO), blood eosinophils, and serum periostin, respectively. After 48 weeks of omalizumab, reductions in protocol-defined exacerbations were greater in high versus low subgroups for all three biomarkers: FE(NO), 53% (95% confidence interval [CI], 37-70; P = 0.001) versus 16% (95% CI, -32 to 46; P = 0.45); eosinophils, 32% (95% CI, 11-48; P = 0.005) versus 9% (95% CI, -24 to 34; P = 0.54); and periostin, 30% (95% CI, -2 to 51; P = 0.07) versus 3% (95% CI, -43 to 32; P = 0.94). The difference in exacerbation frequency between omalizumab and placebo was greatest in the three high-biomarker subgroups, probably associated with the greater risk for exacerbations in high subgroups. Additional studies are required to explore the value of these biomarkers in clinical practice. Clinical trial registered with www.clinicaltrials.gov (NCT00314574).Keywords
This publication has 35 references indexed in Scilit:
- Narrative Review: The Role of Th2 Immune Pathway Modulation in the Treatment of Severe Asthma and Its PhenotypesAnnals of Internal Medicine, 2010
- Lessons learned from variation in response to therapy in clinical trialsJournal of Allergy and Clinical Immunology, 2010
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- The cytokine network in asthma and chronic obstructive pulmonary diseaseJCI Insight, 2008
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- Can Guideline-defined Asthma Control Be Achieved?American Journal of Respiratory and Critical Care Medicine, 2004
- Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthmaExpert Opinion on Pharmacotherapy, 2004
- Significant variability in response to inhaled corticosteroids for persistent asthmaJournal of Allergy and Clinical Immunology, 2002
- AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Inhibition of Allergic Reactions with Antibodies to IgEInternational Archives of Allergy and Immunology, 1995